ArticleTherapeutic advances in musculoskeletal disease2021
Ten-year survival analysis of patients with primary Sjögren's syndrome in China: a national prospective cohort study.
Article in Therapeutic advances in musculoskeletal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.American journal of respiratory and critical care medicine · 2025Guideline
- Anatomy of a Cohort: 40-Year Follow-Up of a Sjögren's Cohort.Journal of clinical medicine · 2026Article
- Sex differences in primary Sjögren's disease: prognostic impact on mortality and cancer.Biology of sex differences · 2026Observational
- Primary Sjögren's syndrome-associated immune thrombocytopenia: from pathogenesis to treatment.Frontiers in immunology · 2026Review
- Clinical features, diagnosis, and treatment of primary Sjögren's disease with interstitial lung disease: A narrative review.Frontiers in immunology · 2026Review
- Clinical characteristics and risk factors for the bidirectional association between immune thrombocytopenia and Sjögren's syndrome.Clinical rheumatology · 2025Article
- Is high IgG level associated with disease activity and organ damage in patients with Sjögren's syndrome? A 3-year follow-up cohort study.Clinical and experimental medicine · 2025Article
- Clinical Characteristics and Risk Factors ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Time-Dependent Mortality Predictors in Primary Sjögren's Syndrome: C-Reactive Protein for Early Risk and Age for Late Outcomes.Journal of inflammation research · 2025Article
- Article
- Immunometabolic alteration of CD4Clinical and experimental medicine · 2024Article
- Identification and Validation of IFI44 as a Novel Biomarker for Primary Sjögren's Syndrome.Journal of inflammation research · 2024Article
- An Early View of Iran Primary Sjogren Syndrome Registry (Guilan Province Pilot Phase), an Emerging Effort for a National Registry Establishment.Medical journal of the Islamic Republic of Iran · 2024Article
- Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study.EClinicalMedicine · 2023Article
- Anti-SSA/SSB-negative primary Sjögren's syndrome showing different clinical phenotypes: a retrospective study of 934 cases.Advances in rheumatology (London, England) · 2023Article
- Screening biomarkers for Sjogren's Syndrome by computer analysis and evaluating the expression correlations with the levels of immune cells.Frontiers in immunology · 2023Article
- Clinical and laboratory evaluation of sicca complaints: distinctive aspects of primary, secondary and non-Sjogren syndrome.Advances in rheumatology (London, England) · 2022Article
- A Decreased Absolute Number of TAdvances in therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the long-term survival of patients with primary Sjögren's syndrome (pSS) in China.
methodsPatients with pSS who fulfilled the 2002 American-European Consensus Group classification criteria were prospectively enrolled from 2004 to 2011. Their baseline clinical, laboratory, and therapeutic data were collected. The primary endpoint was all-cause death by January 2018. The standard mortality ratio (SMR) was calculated by comparing with age-matched and sex-matched mortality data of the general population. Kaplan-Meier curves were obtained by time-to-event analysis. Univariate and multivariate Cox hazards regression analyses were performed to identify risk factors for mortality.
resultsA total of 1054 patients were enrolled and 834 patients were followed up for a median of 94.8 months, with 48 confirmed deaths. The total SMR was 3.63 [95% confidence interval (CI) 2.60-4.66]. The 3-, 5-, and 10-year survival rates were 98.4%, 97.5%, and 92.9%, respectively. Infection, malignancy, and respiratory failure were the top three causes of mortality. We identified male sex [hazard ratio (HR) = 3.00, 95% CI 1.23-7.31], age at diagnosis ⩾50 years of age (HR = 7.69, 95% CI 3.01-19.62), thrombocytopenia (HR = 1.93, 95% CI 1.01-3.72), and interstitial lung disease (HR = 5.96, 95% CI 2.24-15.82) as the independent prognostic factors of death.
conclusionsThe mortality rates of Chinese patients with pSS are higher than those of the general population. Male patients of elder age at diagnosis complicated with thrombocytopenia and interstitial lung disease might be suggestive for poorer survival and require closer follow up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.